Nadine McGrath On February 4, 2022 SocPo’s Powerplays: Who’s...

Nadine McGrath
On February 4, 2022
SocPo’s Powerplays: Who’s making a gritty comeback?

On the positive side Impedimed (ASX:IPD) has risen ~12.5% to 18 cents this week on the back of positive Q2 FY22 results. Furthermore, the company has seen its PREVENT trial results peer-reviewed and published in the journal Lymphatic Research ad Biology.
The trial showed intervention in patients with early detection of cancer-related lymphoedema using Impedimed’s L-Dex technology resulted in a lower rate of progression to chronic disease, compared to patients with early detection from volume measurements using a tape measure.

“The trial was finished about 12 months ago and they had been trying to get it peer reviewed and published into one of the medical journals and it’s taken longer than expected but it was a turning point for them,” Power said.

“It helps their case for the private insurers to adopt the technology and they are also going to make an application to the body which makes the guidelines as to how cancer gets treated.”